BaseSpace
Correlation Engine 2.0
Import Your Data
QuickView

FAQ

More QuickView FAQs

Back to top
Clear Search sequence regions
(e.g. CXCL2, Response to oxidative stress, Hepatitis, Heart, Biofuel, Valproic acid)
Bookmark Forward

QuickView for BRAF (gene)


Body Atlas

Most Correlated Tissues

  1. Cerebellar hemisphere
  2. Cerebellar vermis
  3. Cerebellum
  4. Thalamus lateral nuclei
  5. Prefrontal cortex
Explore Body Atlas Results

Disease Atlas

Most Correlated Diseases

  1. Cardio-facio-cutaneous syndrome
  2. Lentigo
  3. Hyperpigmentation of skin
  4. Noonan's syndrome
  5. Turner syndrome
Explore Disease Atlas Results

Pharmaco Atlas

Most Correlated Compounds

  1. Oxyphenisatin Acetate
  2. phensuximide
  3. si-wu-tang
  4. Maneb
  5. sangivamycin
Explore Pharmaco Atlas Results

Knockdown Atlas

Most Correlated Gene Perturbations

  1. TLX3
  2. AKT3
  3. DCAF1
  4. EIF4EBP2
  5. EIF4EBP1
Explore Knockdown Atlas Results

Curated Studies

Most Correlated Studies

Loading...
Explore Curated Studies Results

Literature

Most Relevant Literature

  1. Computational analysis of natural product B-Raf inhibitors.
  2. Design, synthesis and characterisation of a novel type II B-RAF paradox breaker inhibitor.
  3. Recent advances in B-RAF inhibitors as anticancer agents.
  4. A B-Raf V600E gene signature for melanoma predicts prognosis and reveals sensitivity to targeted the…
  5. Function and evolution of B-Raf loop dynamics relevant to cancer recurrence under drug inhibition.
Explore Literature Results

Clinical Trials

Most Relevant Clinical Trials

  1. Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Me…
  2. Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma
  3. Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma
  4. ENCOrafenib With Binimetinib in bRAF NSCLC
  5. LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trame…
Explore Clinical Trials Results
  • Copyright © 2023 Illumina Inc. All rights reserved.